title: Facial volume augmentation in 2014: overview of different filler options.
abstract: Volume loss is considered to be one of the major contributors to facial aging. Therefore, the restoration of facial volume and contour changes has become an important treatment approach in aesthetic dermatology in recent years. In October 2013 the FDA approved for the first time ever an injectable dermal filler for the augmentation of age-related volume loss. This low-molecular-weight (LMW) 20 mg/ml hyaluronic acid (HA) filler competes on the market with poly-L-lactic acid (PLLA) and calcium hydroxylapatite (CaHA), that have been used off-label for many years to restore age-related volume loss. The safety profile and efficacy of all three injectables has been intensively evaluated in innumerous clinical studies. However, each volume filler has its benefits and disadvantages, including usage, method of action and duration of effect that are reviewed in this article.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Luebberding
authors.forename: Macrene
authors.initials: M
authors.lastname: Alexiades-Armenakas
mesh_terms: D000375:Aging; D003357:Cosmetic Techniques; D017886:Durapatite / Q000008:administration & dosage* / Q000009:adverse effects; D005145:Face; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D007267:Injections; D019344:Lactic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D056687:Off-Label Use; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage* / Q000009:adverse effects; D015595:Skin Aging; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide); D006820:Hyaluronic Acid; D017886:Durapatite